Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 6/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138689 | 0.82 | ALDH1A1 (0.50) | FBP1ALDH1A1LMNAMAPTNSD1 | |
| SCHEMBL4139303 | 0.82 | HSD17B10 (0.50) | FBP1ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL4123151 | 0.82 | NSD1 (0.51) | CYP2C19FBP1ALDH1A1LMNAMAPT | |
| SCHEMBL4134264 | 0.80 | FBP1 (0.42) | CYP2C19FBP1ALDH1A1LMNAMAPT | |
| SCHEMBL4128702 | 0.80 | NPC1 (0.42) | CYP2C19FBP1ALDH1A1LMNANPC1 | |
| SCHEMBL23628947 | 0.79 | TOP2A (0.55) | CYP2C19TOP2ACYP2D6CYP2C9 | |
| SCHEMBL20554137 | 0.79 | CYP3A4 (0.51) | CYP2C19MAPTNSD1CSNK2A1 | |
| SCHEMBL4140328 | 0.78 | FBP1 (0.44) | CYP2C19FBP1ALDH1A1LMNANPC1 | |
| SCHEMBL4289343 | 0.76 | TDP1 (0.56) | FBP1ALDH1A1LMNAMAPT | |
| SCHEMBL23195868 | 0.75 | NPC1 (0.42) | CYP2C19ALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | CYP2C19 920/4885FBP1 1/4885TOP2A 3771/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | CYP2C19 726/4885FBP1 1/4885TOP2A 3801/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | CYP2C19 726/4885FBP1 1/4885TOP2A 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.